IPP Bureau
USFDA accepts Blenrep combinations for treatment of relapsed/refractory multiple myeloma
By IPP Bureau - November 25, 2024
If approved, Blenrep (belantamab mafodotin) in combinations with BorDex (BVd) and PomDex (BPd) could redefine multiple myeloma treatment at or after first relapse
Amalgamation of Gujarat Themis Biosyn with Themis Medicare
By IPP Bureau - November 23, 2024
The Scheme is subject to approval of the secured creditors and shareholders of TML and GTBL
AstraZeneca Pharma Pharma India to launch Breztri Aerosphere in Jan 2025
By IPP Bureau - November 23, 2024
IMCD expands its Pharmaceuticals Technical Centre in Jakarta
By IPP Bureau - November 23, 2024
The centre features a cutting-edge climatic chamber for stability testing and spectrophotometry to ensure that products meet the most stringent manufacturing and testing standards
Merck recommends rejection of TRC Capital’s “Mini-Tender” Offer
By IPP Bureau - November 23, 2024
The offer price is approximately 4.32% below the closing price of the Merck common stock on November 11, 2024
JHU signs MoU with Ajit Isaac Foundation to bring essential palliative care services to rural India’s terminally ill
By IPP Bureau - November 22, 2024
The collaboration offers opportunities for training, research fellowships, workshops and conferences at palliative care centers managed by Ajit Isaac Foundation
Sartorius Stedim Biotech opens center for bioprocess innovation in USA
By IPP Bureau - November 22, 2024
New research labs and process development services to enable next generation therapeutics
Strides Pharma Science appoints Dr. C. Muthulingam as Executive VP - R&D
By IPP Bureau - November 22, 2024
Dr. Muthu was last associated with Mankind Pharma
Merck Life Science India ink MoU with GeNext Genomics
By IPP Bureau - November 22, 2024
Genext Genomics can now offer comprehensive solutions that support the growth of India’s biotech ecosystem
Azenta obtains regulatory approval for clinical long-read whole genome sequencing test
By IPP Bureau - November 22, 2024
Performed within GENEWIZ from Azenta Life Sciences' CLIA-certified and CAP-accredited state-of-the-art clinical genomics laboratory
Converge Bio raises $5.5M Seed to speed up drug discovery and development with Generative AI
By IPP Bureau - November 22, 2024
Bringing a new drug to market takes about 10 years and requires an investment of approximately $1 billion
Siegfried opens global R&D Center for Drug Substances in Switzerland
By IPP Bureau - November 21, 2024
The new facility significantly increases Siegfried’s R&D capacity to drive development excellence and further growth
Emcure and MS Dhoni drive India’s fight against Anemia
By IPP Bureau - November 21, 2024
Emcure has launched an awareness campaign to help spread the word about male anemia
Informa Markets in India set to host 17th edition of CPHI & PMEC India Expo
By IPP Bureau - November 21, 2024
CPHI & PMEC India Expo 2024 to bring over 50,000 industry professionals and 2,000 exhibitors under one roof
Pfizer appoints Chris Boshoff as Chief Scientific Officer and President, Research & Development
By IPP Bureau - November 21, 2024
Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer
